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Hypervirulent Klebsiella pneumoniae (hvKp) is globally disseminating
as a community-acquired pathogen causing life-threatening infec-
tions in healthy individuals. The fact that a dose as little as 50 bacteria
is lethal to mice illustrates the dramatic increase of virulence associ-
ated with hvKp strains compared with classical K. pneumoniae (cKp)
strains, which require lethal doses greater than 107 bacteria. Until
recently, these virulent strains were mostly antibiotic-susceptible.
However, multidrug-resistant (MDR) hvKp strains have been emerg-
ing, spawning a new generation of hypervirulent “superbugs.” The
mechanisms of hypervirulence are not fully defined, but overproduc-
tion of capsular polysaccharide significantly impedes host clearance,
resulting in increased pathogenicity of hvKp strains. While there are
more than 80 serotypes of K. pneumoniae, the K1 and K2 serotypes
cause the vast majority of hypervirulent infections. Therefore, a
glycoconjugate vaccine targeting these 2 serotypes could signif-
icantly reduce hvKp infection. Conventionally, glycoconjugate
vaccines are manufactured using intricate chemical methodologies
to covalently attach purified polysaccharides to carrier proteins,
which is widely considered to be technically challenging. Here we re-
port on the recombinant production and analytical characterization of
bioconjugate vaccines, enzymatically produced in glycoengineered
Escherichia coli cells, against the 2 predominant hypervirulent
K. pneumoniae serotypes, K1 and K2. The K. pneumoniae bioconju-
gates are immunogenic and efficacious, protecting mice against le-
thal infection from 2 hvKp strains, NTUH K-2044 and ATCC 43816.
This preclinical study constitutes a key step toward preventing fur-
ther global dissemination of hypervirulent MDR hvKp strains.
glycoconjugate | bioconjugation | vaccine | hypervirulent
Klebsiella pneumoniae
Klebsiella pneumoniae is an encapsulated, Gram-negativebacterium of the Enterobacteriaceae family recognized
as an opportunistic pathogen causing nosocomial infections (1).
K. pneumoniae is notorious mostly due to the emergence of
carbapenem-resistant strains (2); however, the rise and global
dissemination of a hypervirulent form of K. pneumoniae is alarming
(3). While the majority of K. pneumoniae infections manifest in the
hospital setting or in immunocompromised individuals (termed
classical K. pneumoniae [cKp] infection), a subset of highly invasive,
community-acquired K. pneumoniae infections, termed hyperviru-
lent K. pneumoniae (hvKp) infections, are steadily increasing in
frequency (3).
First observed in the 1980s in Taiwan, hvKp infections are
pyogenic and mainly present as hepatic abscesses that can be
complicated by endophthalmitis, meningitis, osteomyelitis, and
necrotizing fasciitis (4–7). One of the most notable bacterial phe-
notypes associated with hvKp is the overproduction of the capsular
polysaccharide (CPS) (8), which results in a hypermucoviscous
phenotype. This phenotype can be demonstrated by a positive
string test: a greater than 5 mm “string” between an inoculating
loop and a plated bacterial colony (9). Overproduction of the CPS
has been directly linked with increased resistance to host clearance
via impaired complement-mediated bacterial killing (10) and
phagocytosis by neutrophils and macrophages (11).
More than 80 K. pneumoniae CPS serotypes have been iden-
tified (12); however, only 2 serotypes, the K1 and K2 serotypes,
are responsible for the vast majority of hvKp infections. In fact,
K1 and K2 serotypes have been associated with ∼70% of all
hvKp infections across many clinical institutions worldwide (8,
13–15). Additionally, while these infections have historically
been susceptible to most antibiotic classes, there are now increasing
reports emerging of hvKp strains acquiring multiple antibiotic-
resistance determinants, rendering them refractory to most thera-
peutic regimens (16, 17). Given the severity of disease associated
with hvKp infections; their propensity for young, healthy hosts;
the increasing rise of drug resistance in hvKp strains;
and the observation that the majority of hvKp infections are
caused by 2 serotypes, a bivalent glycoconjugate vaccine against
the K1 and K2 serotypes would be an optimal prophylactic
option.
Glycoconjugate vaccines, composed of a bacterial polysaccharide
covalently attached to a carrier protein, are lifesaving prophylactic
agents used to prevent colonization and disease by certain bacterial
pathogens. Moreover, glycoconjugate vaccines elicit immunological
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memory in all age groups, including infants and children, which is
not the case for purely polysaccharide vaccines (18). Traditionally,
glycoconjugate vaccines have been manufactured via chemical
conjugation (19); however, this process requires the use of
complex/multiple-step chemical protocols, making them labor-
intensive, ultimately hindering the timely development of next-
generation conjugate vaccines against emerging bacterial threats
like hvKp (20). As an alternative, we and others have been
developing methods to generate glycoconjugate vaccines by
exploiting prokaryotic glycosylation systems in a process termed
bioconjugation (21).
Bioconjugation relies on a conjugating enzyme, known as an
oligosaccharyltransferase (OTase), to transfer polysaccharides
from lipid-linked precursors to carrier proteins, all within the
periplasm of Gram-negative bacterial expression systems such as
Escherichia coli. Three conjugating enzymes have been utilized
for bioconjugate vaccine development: PglB, PglL, and PglS (21–
23). Each OTase has unique properties enabling the transfer of
different polysaccharide substrates to different carrier proteins.
At least 2 bioconjugate vaccines are being tested in human
clinical trials: Flexyn2a (24) and ExPEc4V (25), which target
Shigella flexneri and extraintestinal E. coli, respectively. Many
more bioconjugate vaccines are in different stages of preclinical
development (26, 27). The overwhelming majority of these are
being developed using PglB and, to a limited extent, PglL.
However, both PglB and PglL are unable to conjugate polysac-
charides containing glucose at the reducing end (the first sugar in
the growing polysaccharide chain), such as most of the Strepto-
coccus pneumoniae (28) and the K1 and K2 Klebsiella capsules
(12). Recently, we identified a new class of conjugating enzyme,
termed PglS, that is capable of transferring a diverse array of
polysaccharides, including those that contain glucose as the re-
ducing end sugar (23, 29). Importantly, more than 50% of all K.
pneumoniae capsular serotypes are composed of polysaccharides
with glucose at the reducing end, including both the K1 and
K2 serotypes (12). Thus, PglB and PglL cannot be used to gen-
erate a bioconjugate vaccine against hvKp.
Here we sought to develop a first-of-its-kind bioconjugate
vaccine against hvKp infection. We have glycoengineered strains
of E. coli for the recombinant production of a bivalent K1/K2 K.
pneumoniae bioconjugate vaccine. We present data on our
glycoengineering approach and the analytical characterization
of the resultant K1/K2 bioconjugate vaccines, and demonstrate
the efficacy of the hvKp biconjugate vaccines in a murine model
of infection.
Results
Glycoengineered Strains of E. coli Require RmpA for Heterologous
K1 and K2 CPS Expression. Prokaryotic glycoengineering exploits
conserved polysaccharide synthesis and export pathways for the
reprogrammable assembly and transfer of designer glycans in E.
coli (SI Appendix, Fig. S1). The first step in glycoengineering
bioconjugate vaccines against hvKp required building strains of
E. coli for the heterologous expression of the K1 and K2 K.
pneumoniae CPSs. As such, we cloned the K1 and K2 CPS loci
from K. pneumoniae NTUH K-2044 (30) and K. pneumoniae
52.145 (31), respectively (Fig. 1 A and B). The cloned K1 CPS
locus contained the genes from wzx to ugd. The cloned K2 CPS
locus contained the genes from wcuF to ugd. The CPS regulatory
genes wza, wzb, and wzc and export gene wzi are not required for
heterologous CPS expression in E. coli (32) and were not in-
cluded in the constructs. The galF and orf2 genes were also ex-
cluded because E. coli carries its own copy of galF and the role of
orf2 in K. pneumoniae CPS production is unclear. The plasmids
containing the biosynthesis machinery for the K1 or K2 CPS
were then introduced into E. coli CLM37, a reporter strain for
heterologous polysaccharide expression and assembly (33).
CLM37 cannot produce its natural O16 antigen due to a mu-
tation in the WecA initiating glycosyltransferase. However,
CLM37 expresses the WaaL O antigen ligase that transfers
lipid-linked polysaccharides, like the K1 and K2 polysaccha-
rides, to the outer core saccharide of LPS (34). After IPTG
induction and overnight growth, LPS was extracted, separated
by SDS/PAGE, and silver-stained from CLM37 cells expressing
either the K1 or K2 CPS plasmids. As seen in Fig. 1 C and D, no
appreciable O antigen polysaccharide was observed. We de-
tected only the core saccharide, indicating that the K1 and
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Fig. 1. RmpA enhances expression of the K1 and K2 glycans in E. coli CLM37. (A) The K. pneumoniae K1 CPS gene map and (B) the K. pneumoniae K2 CPS
gene map. Black arrows indicate UDP-sugar biosynthesis genes, purple arrows indicate CPS regulatory/surface export genes, orange arrows indicate transport/
polymerase genes, blue arrows indicate glycosyltransferase genes, and green arrows indicate initiating glycosyltransferase genes. (C) Silver staining and
Western blot analysis of LPS extracted from CLM37, CLM37 expressing the K1 locus, or CLM37 coexpressing the K1 locus and RmpA. (D) Silver staining of LPS
extracted from CLM37, CLM37 expressing the K2 locus, or CLM37 coexpressing the K locus and RmpA.
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WaaL ligase. Given that the WaaL has highly relaxed substrate
specificity, we hypothesized that the absence of K1 and
K2 polysaccharides was due to their poor expression. Pre-
viously, Arakawa et al. demonstrated that the K2 CPS could be
detected on the surface of E. coli JM109 when the complete
K2 locus and the transcriptional activator RmpA were coex-
pressed (35). Therefore, we cloned rmpA from K. pneumoniae
NTUH K-2044 (NCBI accession no. BAH65944) into pACT3, a
low-copy IPTG-inducible vector, and introduced this plasmid
into CLM37 strains containing the K1 or K2 CPS-expressing
plasmids. When RmpA was coexpressed with either the K1 or
K2 CPS expressing plasmids in CLM37, purified LPS contained
observable O antigen polysaccharides (Fig. 1 C and D). Fur-
ther, Western blot analysis using the monoclonal antibody 4C5,
specific to the K1 CPS of K. pneumoniae (36), reacted with LPS
purified from CLM37 coexpressing the K1 CPS locus and
RmpA, indicating that the polysaccharide produced by this
glycoengineered E. coli strain has a K1 structure. There are
no commercially or publicly available antibodies to the K2
polysaccharide.
Fig. 2. Two-dimensional NMR analysis of K1- and K2-containing LPS extracted from CLM37. (A) The core structure of the K1 repeat unit. (B) The 1H-13C HSQC
spectrum of K. pneumoniae K1 polysaccharide produced in E. coli. Signals of the 2 variable O-acetylated fucoses are not shown because of low signal intensity.
(C) NMR data for the K. pneumoniae K1 polysaccharide and the E. coli core (D2O, 25 °C, 600 MHz). Data for the main structure with O-acetylation (OAc) at
Fucose A O-3. OAc 2.08/21.6 ppm. (D) The core structure of the K2 repeat unit. (E) The 1H-13C HSQC spectrum of K. pneumoniae K2 polysaccharide produced in
E. coli (D2O, 35 °C, 600 MHz). (F) NMR data for the K. pneumoniae K2 polysaccharide and the E. coli core (D2O, 35 °C, 600 MHz).









NMR Analysis of Glycoengineered K1 and K2 LPS and the K. pneumoniae
NTUH K-2044 CPS.Next, we characterized the K1- and K2-containing
LPSs purified from the glycoengineered strains of CLM37. The
published structure of the K. pneumoniae NTUH K-2044 K1 CPS
repeat unit has been reported as (→3)-β-D-Glc-(1,4)-[2,3-(S)-
pyruvate]-β-D-GlcA-(1,4)-α-L-Fuc-(1→) with varying degrees of
acetylation at the C2-OH and C3-OH of the fucose residue (37, 38).
The NMR spectra and chemical shifts for the K1-containing LPS
(Fig. 2 A–C) contained many signals from the core saccharide due
to the short K1 polysaccharide chains, which can also be observed
as low molecular weight polysaccharides on the silver-stained K1-
containing LPS (Fig. 1C). Analysis of the 2D spectra (gCOSY,
TOCSY, NOESY, 1H-13C HSQC, 1H-13C HMBC) allowed for the
identification of the K1 repeating units containing the structure -3-
β-Glc-4-β-GlcA-4-α-L-Fuc2/3OAc-, where fucose was present in
3 variants: nonacetylated or acetylated at positions 2 or 3. The
published structure of the K1 CPS includes the same repeating
unit as well as pyruvylation at the O-2, O-3 positions of the
glucuronic acid (GlcA) residue. Although the spectra contained
small signals attributable to pyruvate, there was no indication
that it was linked to the GlcA residue or any other mono-
saccharide of the repeating unit. Given the varying degrees of
acetylation and pyruvylation between the previously published
K1 structures (37, 38), we purified the capsular polysaccharide
from K. pneumoniae NTUH K-2044 and reexamined it by
NMR analysis. The NMR analysis (SI Appendix, Fig. S2)
showed an identical structure to the K1-containing LPS without
pyruvylation. Acetylation of the fucose was evident with O-
acetylation at the O-2 (∼20%, A″) and the O-3 (∼40%, A′) of
fucose, while the rest of fucose (A) was not acetylated. Small
signals of terminal fucose A* were also visible. Last, signals of
B4 and B5 were shifted between the native and deacylated
K1 polysaccharide, likely due to different pH or salt formations
by glucuronic acid. The data obtained here indicate that the
polysaccharide structures produced by the K1 glycoengineered
strain of E. coli and that of the K. pneumoniae K1 are nearly
identical.
The K2-containing LPS was also extracted from glycoengineered
E. coli CLM37 cells and analyzed by NMR to determine structure
and linkage. As shown in Fig. 2 D–F, the K2 polysaccharide
matched perfectly with the published structure of the native K2
polysaccharide (39).
Glycoengineering a K1 and K2 Bioconjugate Vaccine in E. coli. Pre-
viously, we established a bioconjugation system for transferring poly-
saccharides containing glucose at the reducing end to carrier proteins
(23). The system employs the use of the oligosaccharyltransferase
PglS from Acinetobacter baylyi ADP1 to transfer polysaccharides
from a lipid-liked precursor to a genetically deactivated variant of
exotoxin A protein from Pseudomonas aeruginosa (EPA) fused to
a fragment of ComP, the natural acceptor protein of PglS. As
such, we introduced either the K1 or the K2 CPS-expressing
plasmid along with the transcriptional activator RmpA into a
glycocompetent strain of E. coli, strain SDB1, expressing the PglS
bioconjugation platform. SDB1 is ΔwaaL derivative of CLM37,
which prevents the use of the capsule for LPS synthesis. After
induction and overnight growth, K1-EPA and K2-EPA glycopro-
teins were purified using affinity, anionic exchange, and size-
exclusion chromatography and examined by Coomassie staining
and Western blotting. As seen in Fig. 3A, the unglycosylated EPA
fusion protein migrates between the 75-kDa and 95-kDa markers
(the theoretical molecular weight is 75,526.15 Da). The K1-EPA
glycoprotein existed almost entirely as a semihomogenous glyco-
form with a smeared electrophoretic mobility slightly larger than
the 95-kDa marker. A similar electrophoretic mobility was also
observed for the K1-containing LPS; however, more resolution
can be seen due to the fact that the K1-containing LPS was sep-
arated by using a 15% polyacrylamide gel whereas the K1-EPA
glycoprotein was resolved on an 8% polyacrylamide gel. While this
presentation for a bioconjugate vaccine is unusual, the smear-like
banding is commonly observed for glycoconjugate vaccines pre-
pared with chemical methodologies and is likely a product of
nonstoichiometric levels of acetylation and pyruvylation of the
K1 repeat unit. Western blotting using the 4C5 monoclonal anti-
body specific to the K1 capsule confirmed that the K1-EPA bio-
conjugate was indeed carrying K1 glycans (Fig. 3 B–D). The K2-
EPA glycoprotein ran more similarly to conventional bioconjugate
vaccines, exhibiting a modal, ladder distribution with each band
corresponding to a glycoform with an additional K2 subunit.
Intact Mass Spectrometry of Bioconjugate Vaccines. Due to the lack
of polyclonal or monoclonal antibodies specific to the K2 glycan,
we next performed intact mass spectrometry analysis on the K2-
EPA bioconjugate. This technique provides analytical data on the
relative glycosylation ratios for bioconjugates existing in multiple
different glycoforms as well as relative masses associated with each
glycoform. As seen in Fig. 4A, the intact mass spectrum of the K2-
EPA bioconjugate showed a modal, ladder distribution of K2-
EPA bioconjugates, each separated by ∼662 Da, the mass of the
K2 repeat unit (39). As many as 12 K2 repeat units were observed
to be covalently attached to the EPA carrier protein by mass
spectrometry; however, analysis of the Coomassie-stained purified
glycoprotein preparation indicates that as many as 16 repeat units
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A B C D
Fig. 3. K1-EPA and K2-EPA bioconjugate vaccines. (A) Coomassie-stained image of purified EPA, K1-EPA, and K2-EPA. Each lane was loaded with ∼5 μg of
glycoconjugate based on total protein. The unglycosylated EPA exists a single band. The K1-EPA exists as multiple glycoforms migrating in smear-like pattern.
The K2-EPA bioconjugate migrates with a modal, ladder distribution. Each lane was loaded with ∼0.5 μg of glycoconjugate based on total protein. (B–D)
Western blot analysis probing for EPA and the K1 glycan. (B) Anti-EPA Western blot, (C) anti-K1 Western blot, and (D) merge image.
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glycoforms showed that the most abundant glycoform contained 2
repeat units, with the next most abundant glycoform containing 7
K2 repeat units (Fig. 4B). Interestingly, when examined collec-
tively, the K2-EPA glycoprotein seemed to be glycosylated with
the K2 glycan in a semi–bell-curve distribution, indicating that PglS
may prefer certain-sized lipid-linked polysaccharides as substrates.
We also performed intact mass spectrometry on the K1-EPA
bioconjugate. The EPA fusion protein was observed as a series
of peaks compatible with different glycoforms containing the in-
herently heterogenous K1 repeat units, which is nonstoichio-
metrically modified with acetylation at the fucose residue and/or
pyruvylated at the glucuronic acid residue (SI Appendix, Fig. S3).
K1 and K2 Bioconjugates Elicit Serotype-Specific IgG Responses. The
K1-EPA and K2-EPA bioconjugates were then tested for their
abilities to induce serotype-specific IgG responses. Four immu-
nization groups, each containing 5 mice, were vaccinated with
either a placebo (the unglycosylated EPA fusion protein), the
K1-EPA bioconjugate, the K2-EPA bioconjugate, or a bivalent
mixture of the K1- and K2-EPA bioconjugates. All vaccines were
coformulated with an equal mixture of Imject Alum as an adjuvant
(50 μL vaccine to 50 μL alum). The EPA-alone group, K1-EPA
group (222 ng of K1 glycan), and K2-EPA group (195 ng of
K2 glycan) all received 5 μg of vaccine based on total protein
quantity. The total polysaccharide content was measured using a
modified anthrone-sulfuric assay (40). The bivalent vaccine was
formulated by combining the K1-EPA and K2-EPA vaccine
doses; thus, bivalent groups received a total of 10 μg of EPA,
222 ng of K1 glycan, and 195 ng of K2 glycan. Mice were vac-
cinated 3 times s.c. on days 0, 14, and 28 and killed on day 42.
Serum was collected throughout the course of the trial and used
to characterize the IgG responses via ELISA with plates coated
with either K. pneumoniae NTUH K-2044 (K1) or K. pneumoniae
ATCC 43816 (K2) whole cells.
As seen in Fig. 5, mice vaccinated with K1-EPA bioconjugates
had increased K1-specific IgG titers compared with mock-
vaccinated mice. Mice receiving the bivalent K1-/K2-EPA vac-
cine also had similar increases in K1-specific IgG titers compared
with mock-vaccinated mice. The response was slightly lower than
that of the single K1-EPA vaccinated group, but no statistically
significant difference was observed. No K2-specific cross-reactivity
was observed for K1-EPA vaccinated mice. In addition, mice
g0
g2
g3 g4 g5 g6 g7 g8 g9 g10 g11 g12
A
B
Fig. 4. Mass spectrometry analysis of K2-EPA. (A) Intact protein mass spectrometry analysis showing the MS1 mass spectra for K2-EPA. The EPA fusion protein
has a theoretical mass of 79,526.15 Da and can be observed as the peak at 79,518.73 Da. The EPA fusion protein was also observed in multiple states of
increasing mass corresponding to the K2 repeat unit, which has a mass of 662 Da. Varying glycoforms of K2-EPA were observed and are denoted by “gnumeric”,
where “g” stands for glycoform and the “numeric” corresponds to the number of repeating CPS8 subunits. (B) Quantification of the relative abundance of
each K2 glycoform.









vaccinated with the K2-EPA biconjugate had increased K2-
specific IgG titers compared with mock-vaccinated mice; how-
ever, 1 mouse receiving the K2-EPA vaccine did not show in-
creases in K2-specific IgG titers. Mice receiving the bivalent K1-/
K2-EPA vaccine also had similar increases in K2-specific IgG
titers compared with mock-vaccinated mice. As was the case for
the K2-EPA group, 1 mouse did not show an increase in K2-
specific IgG titers. No K1-specific cross-reactivity was observed
for mice vaccinated with the K2-EPA bioconjugate.
Mice sera were further examined for serotype-specific IgG
kinetics over the course of the vaccination. As seen in Fig. 5, the
kinetics of K1-specific total IgG responses increased over time,
with K1-EPA vaccinated mice showing a more robust response
compared with bivalent K1-EPA/K2-EPA vaccinated mice. The
kinetics of total IgG responses specific to K2 were also mea-
sured, and a similar trend was observed, with mice vaccinated
with the K2-EPA bioconjugate showing the most robust response
compared with bivalent vaccinated mice.
Next, mouse sera were pooled and examined by whole-cell
ELISA for IgG subclass distributions specific to the K1 or
K2 antigen. As seen in SI Appendix, Fig. S4, pooled K1-EPA
vaccinated sera and pooled K1-/K2-EPA vaccinated sera dis-
played an exclusively IgG1-specific response to the K1 antigen.
The same trend was also observed for the pooled K2-EPA and
pooled K1-/K2-EPA vaccinated sera when probing for specificity
to the K2 antigen.
K1/K2 Bioconjugate Vaccines Protect Mice from hvKp Infection. The
correlates of immunity that confer protection from classical or
hypervirulent K. pneumoniae infection are not known. Therefore,
we evaluated the protectiveness of the bivalent K1-/K2-EPA
vaccine using a murine acute pulmonary infection model with
2 separate hypervirulent K. pneumoniae strains: NTUH K-2044
(K1) and ATCC 43816 (K2). Both strains are hyper-capsule
producers (hypermucoviscous) and extremely virulent in mice.
In fact, the LD50 for both strains has been shown to be less than
100 colony forming units (CFUs) in murine respiratory infection
models (41). Two groups of mice (20 female BALB/c mice per
group) were vaccinated with the carrier protein alone or with the
bivalent K1-/K2-EPA bioconjugate vaccine. Briefly, mice were
vaccinated on days 0, 14, and 28 using the same dosing and ad-
juvant formulation as described above. After the vaccination
regimen, the 2 groups (EPA placebo or bivalent bioconjugate
vaccinated) were then challenged with either the K1 or K2 strain
at doses close to the published LD50 values. Specifically, 10 mice
from each vaccination group were inoculated by aspiration with
the hypervirulent K1 strain (NTUH K-2044) and 10 were in-
oculated with the hypervirulent K2 strain (ATCC 43816) and
subsequently monitored for survival and changes in weight for a
2-wk period (Fig. 6 A and B). As seen in Fig. 6A, 80% of placebo-
vaccinated mice challenged with only 50 CFUs of the hypervirulent
K1 strain (K. pneumoniae NTUH K-2044) succumbed to infec-
tion, whereas only 20% of bioconjugate-vaccinated mice died
(P = 0.0057 by log-rank test). While K. pneumoniae ATCC
43816 was not as virulent in this mouse model as K. pneumoniae
NTUH K-2044, a dose of only 250 CFUs was able to kill 30% of
the placebo-vaccinated mice (Fig. 6B), whereas no mice from the
bioconjugate-vaccinated group challenged with ATCC 43816
died (P = 0.0669 by log-rank test). Additionally, placebo-
vaccinated mice that did survive low-dose challenge had lower
body weights than bioconjugate-vaccinated mice (SI Appendix,
Fig. S5).
Given the success of the bioconjugate vaccine in preventing
death from infection of hvKp at doses close to the LD50
values, we further challenged a separate group of placebo- and
bioconjugate-vaccinated mice with hvKp strains at 100× the
published LD50 titers. For K. pneumoniae NTUH K-2044 (K1),
all of the placebo-vaccinated mice rapidly died (Fig. 6C). The
majority of bioconjugate-vaccinated mice also succumbed to this
high-dose infection; however, the bioconjugate-vaccinated mouse
Fig. 5. IgG responses to K1 and K2 bioconjugate vaccines. (A) Titers of K1-specific IgG antibodies in mice immunized with EPA, K1-EPA, K2-EPA, or a bivalent
K-/K2-EPA. (B) K1-specific IgG kinetics over the course of the immunization as measured by ELISA and quantified by absorbance at 450 nm. (C) Titers of K2-
specific IgG antibodies in mice immunized with EPA, K1-EPA, K2-EPA, or a bivalent K-/K2-EPA. (D) K2-specific IgG kinetics over the course of the immunization
as measured by ELISA and quantified by absorbance at 450 nm.
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group had a statistically significant increase in survival compared
with the placebo-vaccinated group (P = 0.0250 by log-rank test).
When mice were challenged with close to 100× the published
LD50 value of ATCC 43816 (K2), all placebo-vaccinated mice died
by day 4, whereas 5 of the 10 mice survived the infection (P =
0.0038 by log-rank test; Fig. 6D). These data suggest that the
biconjugate vaccine is efficacious in protecting some mice from
K1 or K2 hvKp challenge, even at very high inocula.
Discussion
cKp infections are traditionally associated with nosocomial in-
fections among hospitalized or immunocompromised patients,
while hvKp can target healthy, immunocompetent hosts. Until
recently, hvKp strains have been susceptible to common antibi-
otic agents; however, many cases of carbapenem-resistance and
even colistin-resistance phenotypes in hvKp isolates have been
recently reported (42–45). Furthermore, hvKp strains generated
via the acquisition of hypervirulence plasmids by MDR cKp are
also emerging (16, 17). The extreme virulence of these strains
coupled with a lack of antimicrobial treatment options is worri-
some. As such, vaccines to prevent possible outbreaks of these
hypervirulent, antimicrobial-resistant infections are urgently
needed (46), and possibly prevent the spread of the hypervirulent
plasmid. Here we report on the recombinant production and an-
alytical characterization of rapidly produced bioconjugate vaccines
against the 2 most common hypervirulent serotypes of K. pneu-
moniae (K1 and K2), which account for more than 70% of the
hvKp cases (15). Using a bioconjugation approach in glyco-
engineered E. coli, we show that K1 and K2 bioconjugates are
immunogenic and efficacious, protecting mice from lethal in-
fection from 2 different hypervirulent strains of K. pneumonia.
For efficient bioconjugation of polysaccharides to proteins,
usually only 3 components are needed: an oligosaccharyltransferase
(also known as a conjugating enzyme), a target protein to be
glycosylated, and a polysaccharide to be transferred. However, we
found that a fourth factor, the RmpA transcriptional activator,
was required to efficiently express K1 and K2 capsules in E. coli.
Multiple alleles of rmpA are associated with hypermucoviscous
phenotypes (10, 47). K. pneumoniae isolates can carry as many as 3
different rmpA alleles. One is commonly found on the chromo-
some (rmpAc), whereas 2 plasmid-encoded rmpA alleles (prmpA or
prmpA2) are located on the virulence plasmid found in hypervir-
ulent isolates of K. pneumoniae. In our study, prmpA functioned as
transcriptional activator in glycoengineered E. coli cells; however,
whether rmpAc or prmpA2 would have the same or possibly an
additive effect on K1 and K2 CPS polysaccharide expression has
not been determined.
A few vaccine strategies have been or are in development for
K. pneumoniae. In fact, a 24-valent, purely capsular polysaccharide
vaccine (Klebgen Bema) was developed in the 1980s by the Swiss
Serum and Vaccine Institute and tested in human clinical trials
(48). While the vaccine was shown to elicit increases in serotype-
specific IgG responses in adult cohorts, as frequently happens with
polysaccharide-only vaccines, total serotype-specific IgG levels
dropped to near baseline levels 18 mo after vaccination for many
capsular antigens (48). More recently, a glycoconjugate vaccine
composed of 4 K. pneumoniae OPS serotypes conjugated to fla-
gellin proteins from Pseudomonas aeruginosa was developed (49).
The OPS vaccine was immunogenic, and mice passively trans-
ferred with the OPS vaccine-induced antibodies were protected
against systemic cKp infection. While these preclinical results are
promising, OPS-based vaccines more appropriately target cKp
strains, as molecular studies have shown that the capsular poly-
saccharide of hypervirulent isolates can mask the OPS antigens
(50). Also, it has not been shown that an OPS-based vaccine would
be protective protect against hvKp isolates overproducing capsular
polysaccharide. To the best of our knowledge, the K1-/K2-EPA
bioconjugate presented here is the first case of a vaccine providing
protection from extremely lethal hypervirulent isolates. While our
in vivo work suggests efficacy against hvKp in the lung, additional
studies need to assess efficacy against hvKp in other niches in-
cluding the liver, bloodstream, and meninges.
Glycoconjugate vaccines elicit IgM-to-IgG class switching and im-
munological memory (18). While this is common to all glycoconjugate
Fig. 6. Survival of placebo- and bivalent bioconjugate-vaccinated mice after lethal challenge with hvKp. Groups of mice were vaccinated with either the
placebo or the bivalent K1-/K2-EPA bioconjugate on days 0, 14, and 28. Anesthetized mice were aspirated with either the K. pneumoniae NTUH K-2044 or
ATCC 43816 and monitored for survival for 14 d. For low-dose challenge studies, mice were infected with (A) 50 CFU of NTUH K-2044 or (B) 250 CFU of ATCC
43816. For high-dose challenge studies, mice were infected with (C) 4,700 CFU of NTUH K-2044 or (D) 4,300 CFU of ATCC 43816. Each graph represents data
from a single experiment with n = 10 mice per group. Statistical analysis was performed via log-rank (Mantel–Cox) tests.









vaccines, the distribution of IgG isotypes can be different for each
antigenic stimulus, as well as differ based on the age of the vac-
cinated population. For instance, pneumococcal conjugate vac-
cines elicit strong IgG1 responses in infants and young children
(2–5 y), whereas the same vaccine elicits a predominantly IgG2
response in healthy adults (18–39 y) and geriatric patients (>50 y)
(51). Using 6-wk-old BALB/c mice for our immunization model,
we observed an exclusively IgG1 response for the both the K1 and
K2 antigens. In fact, we were not able to observe any signals for
IgG2a, IgG2b, or IgG3 subclasses by ELISA. IgG1 antibodies are
known to efficiently activate the classical route of complement
(52). Therefore, our data indicate that K1- and K2-specific
IgG1 antibodies may be sufficient to provide protection to vacci-
nated mice challenged with lethal doses of the hvKp isolates.
Future experiments will be needed to establish if high levels
IgG1 can be employed as an appropriate correlate of immunity
and predict protection against hvKp.
While it is currently difficult to define which serotypes should
be included in a capsular polysaccharide glycoconjugate vaccine
targeting cKp infection or determine which populations are most
at risk, the seroepidemiology of hvKp is much clearer. Specifi-
cally, hvKp is endemic to certain parts of Asia, and 2 serotypes,
K1 and K2, have emerged as the highly predominant disease-
causing serotypes (53–55). Moreover, fewer than 10 serotypes
have been reported to be associated with hypervirulent infections
(K1, K2, K5, K16, K20, K54, K57, and KN1) (3). In addition to
the K1 and K2 serotypes, the K5, K16, and K54 serotypes also
contain glucose as the reducing end sugar (12), suggesting that
they may also be appropriate polysaccharide substrates for the
PglS bioconjugation platform. The remaining serotypes (K20,
K57, and KN1) contain galactose at their reducing ends, which are
also compatible with the PglS bioconjugation platform. Therefore,
PglS could be employed to develop a pan-hypervirulent bioconjugate
vaccine against K. pneumoniae. Importantly, the use of the K1-/K2-
EPA bioconjugate would also target K1 and K2 strains of K. pneu-
moniae associated with classical, nosocomial infection. Thus, by
expanding the serotype coverage, a broadly protecting glycoconjugate
vaccine targeting both classical and hypervirulent pathotypes of K.
pneumoniae could be developed rapidly by using our bioconjugation
platform and employed to significantly reduce the burden of K.
pneumoniae disease and possibly slow the rates of drug resistance
and transmission of the hypervirulence plasmid.
The increasing incidence of community-acquired hvKp MDR
strains poses a serious threat to global health. It is imperative
that vaccine strategies to combat hvKp begin immediately, as the
dissemination of the virulence plasmid into the cKp population
could have devastating consequences. Our work demonstrates that
bioconjugation is a promising approach to rapidly developing ef-
ficacious antibacterial vaccines.
Materials and Methods
The bacterial strains, plasmids, and primers used in this study are listed in SI
Appendix, SI Materials and Methods. A full description of all methods
employed for this study is provided in SI Appendix, SI Materials and Meth-
ods. All data are available in the main text or the SI Appendix.
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